Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Profitability Defense Cites Ratio Of Taxes To Revenues

Executive Summary

PhRMA is highlighting the drug industry's relatively high ratio of taxes to revenues in response to a recent intensification in attacks on the industry's profitability.

You may also be interested in...



Tufts R&D Cost Estimate Puts Cash Outlay At $403 Mil. Per NCE

The cash outlay required to complete development of a new chemical entity has increased to an average of more than $400 mil., the Tufts Center for the Study of Drug Development says

Tufts R&D Cost Estimate Puts Cash Outlay At $403 Mil. Per NCE

The cash outlay required to complete development of a new chemical entity has increased to an average of more than $400 mil., the Tufts Center for the Study of Drug Development says

NIH Return-On-Investment Report Will Be Subject Of Senate Hearing This Fall

The Senate Commerce/Science Subcommittee will hold hearings this fall on the return to taxpayers from research funded by the National Institutes of Health.

Related Content

UsernamePublicRestriction

Register

PS038417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel